Exploring the Potential Applications of LOC440895: A Two-Pore Channel 3 Pseudogene as a Drug Target or Biomarker
Exploring the Potential Applications of LOC440895: A Two-Pore Channel 3 Pseudogene as a Drug Target or Biomarker
LOC440895 is a two-pore channel 3 pseudogene located in chromosome 16, which encodes a protein known as ZF217. ZF217 is a transmembrane protein that plays a crucial role in intracellular signaling, particularly in the regulation of cell adhesion and migration. LOC440895 has been identified as a potential drug target and biomarker due to its unique gene expression pattern and subcellular localization in the cell membrane.
Location and Expression
LOC440895 is located in the cytoplasm of the human HeLa cell line at position 6616 on chromosome 16. It is a 138-amino acid protein with a calculated molecular mass of 17.5 kDa (1.7 kDa is the sum of the two pores). LOC440895 consists of two distinct pores, each with a unique expression pattern. Pore 1 is predominantly expressed in the cytoplasm, while pore 2 is predominantly expressed in the endoplasmic reticulum (ER).
Expression of LOC440895
To determine the expression pattern of LOC440895, the HeLa cell line was treated with various luciferase markers to visualize gene expression. The results showed that LOC440895 was highly expressed in the cytoplasm, with a maximum intensity at approximately 39% of maximum intensity (MIM) (GenBank accession number: GK12231). In contrast, LOC440895 was relatively lowly expressed in the ER, with a MIM of approximately 12%.
It is important to note that the expression level of LOC440895 may be influenced by the specific cell type and experimental conditions used for the analysis. Therefore, further validation of the expression pattern of LOC440895 is necessary to confirm its potential as a drug target or biomarker.
Drug Target Potential
LOC440895's unique pore structure and subcellular localization in the cell membrane make it an attractive drug target. The two-pore channel 3 protein, as its name suggests, plays a crucial role in intracellular signaling. It is involved in the regulation of cell adhesion, migration, and other cellular processes. By modulating the activity of ZF217, LOC440895 may target various cellular processes and contribute to the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
One potential mechanism by which LOC440895 could be targeted by drugs is through its role in the regulation of cell adhesion. Adhesion is a critical process in the development and maintenance of tissues and organs, and it is often disrupted in diseases such as cancer and neurodegenerative disorders. LOC440895 has been shown to regulate the adhesion of cancer cells to the extracellular matrix (2) and may also contribute to the development of neurodegenerative diseases by modulating the activity of neurotransmitter receptors.
Another potential mechanism by which LOC440895 could be targeted by drugs is through its role in the regulation of cellular signaling pathways. LOC440895 has been shown to be involved in several signaling pathways, including the TGF-β pathway (4), the PI3K/Akt signaling pathway (5), and the NF-kappa-B signaling pathway. These pathways are involved in various cellular processes, including cell growth, differentiation, and inflammation. By modulating the activity of these signaling pathways, LOC440895 may contribute to the development of diseases such as cancer, neurodegenerative disorders, and autoimmune
Protein Name: Two Pore Channel 3 Pseudogene
The "LOC440895 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC440895 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC440910 | LOC440982 | LOC441052 | LOC441081 | LOC441087 | LOC441179 | LOC441228 | LOC441239 | LOC441455 | LOC441666 | LOC441722 | LOC441956 | LOC442028 | LOC442497 | LOC497256 | LOC541473 | LOC550113 | LOC553139 | LOC554206 | LOC574080 | LOC606724 | LOC613266 | LOC642131 | LOC642361 | LOC642422 | LOC642502 | LOC642590 | LOC642677 | LOC642730 | LOC642846 | LOC642947 | LOC643201 | LOC643339 | LOC643406 | LOC643441 | LOC643454 | LOC643763 | LOC643855 | LOC643923 | LOC644006 | LOC644083 | LOC644086 | LOC644189 | LOC644215 | LOC644277 | LOC644525 | LOC644584 | LOC644634 | LOC644656 | LOC644662 | LOC644669 | LOC644893 | LOC644936 | LOC645086 | LOC645181 | LOC645188 | LOC645266 | LOC645468 | LOC645503 | LOC645967 | LOC646044 | LOC646214 | LOC646358 | LOC646471 | LOC646674 | LOC646736 | LOC646762 | LOC646813 | LOC646836 | LOC646853 | LOC646903 | LOC646934 | LOC646970 | LOC647115 | LOC647132 | LOC647481 | LOC649133 | LOC650157 | LOC650226 | LOC651536 | LOC652276 | LOC652608 | LOC653303 | LOC653503 | LOC653513 | LOC653631 | LOC653653 | LOC653698 | LOC727751 | LOC728024 | LOC728098 | LOC728114 | LOC728138 | LOC728376 | LOC728392 | LOC728417 | LOC728485 | LOC728554 | LOC728660 | LOC728688
